Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Low Prostate-Specific Antigen Screening Has Limited Benefits

By LabMedica International staff writers
Posted on 27 Sep 2010
The epithelial cells in the prostate gland produce the protein prostate-specific antigen (PSA), some of which escapes into the bloodstream. When levels of PSA in the blood are high, it might be an indication of either prostate cancer or some kind of prostate condition.

The level of serum PSA is used as a screening test for diseases that involve the prostate, which include malignant cancer and benign prostatic hyperplasia. A high level of PSA will prompt aggressive therapy including sextant biopsies and biopsies of the affected organ. What constitutes an elevated PSA level varies from country to country.

The European Randomized Study of Screening for Prostate Cancer sections in Finland, Sweden and the Netherlands, screened for intervention 43,987 males, aged 55-70. In Northern Ireland, 42,503 males, aged 55-74 years, were included in the study as clinical participants. They were all followed-up from 1993 and 1999 for prostate cancer incidence and causes of death through to the end of 2006. Men with baseline PSA levels of >20.0 ng/mL were excluded from the study. .

The scientists found that males with low serum PSA levels often undergo biopsies and aggressive treatments, with no significant improvement in mortality, after examining details on 85,000 males aged between 55 and 74 years. The prostate cancer mortality rates intensify with increasing baseline PSA level in both groups. Relative to the men with a baseline serum PSA of <2.0 ng/mL at study entry, men with a higher baseline serum PSA level had a significant, increased, adjusted risk ratio of dying from prostate cancer in both groups. The absolute difference in prostate cancer specific mortality was 0.05 per 10,000 person years in men with a baseline serum PSA level of 0.0 ng/mL - 1.9 ng/mL and 8.88 per 10,000 person years in men with a baseline serum PSA of 10 ng/mL - 19.9 ng/mL, escalating with the increasing baseline PSA level.

For males with PSA levels below 2 ng/mL, in order to prevent just one prostate cancer death, 24,642 patients would need to be screened and 724 patients would need prostate cancer treatment. For men with PSA levels between 10 ng/mL and 19.9 ng/mL, 133 patients would need to be screened to save one life. For men with a low serum PSA level, the benefits of aggressive investigation and treatment may be limited because they are associated with a large increase in cumulative incidence and potential overtreatment.

Pim J. van Leuwen, M.D, Erasmus University Medical Center, (Rotterdam, Netherlands), said, "Screening for prostate cancer has the potential to reduce prostate cancer mortality, but there is a large group of men with a moderately low PSA that will hardly have any benefits of further screening and early detection strategies. In these men, screening and early detection is likely to have little effect on the reduction of prostate cancer mortality, but a major negative effect on the quality of life." The study was published online on September 13, 2010 in the journal Cancer.

Related Links
Erasmus University Medical Center




Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.